Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Core Insights - Verona Pharma plc announces the presentation of ten posters, including seven analyses from its Phase 3 ENHANCE studies on Ohtuvayre (ensifentrine) for COPD treatment at the ATS 2025 conference [1][3] - Ohtuvayre is a first-in-class selective dual inhibitor of PDE3 and PDE4, combining bronchodilator and anti-inflammatory effects, marking the first novel inhaled mechanism for COPD maintenance treatment in over 20 years [2][6] Group 1: Clinical Findings - The ENHANCE posters include subgroup analyses of Ohtuvayre's effects as monotherapy and in patients with comorbid conditions such as cardiac disorders and type 2 diabetes [3] - Ohtuvayre demonstrated improvements in lung function and reduced exacerbation rates in symptomatic patients with moderate-to-severe COPD [4] - A pooled analysis indicated that Ohtuvayre reduced exacerbation rates regardless of FEV1 improvement [4] Group 2: Nonclinical Studies - Nonclinical studies presented include a tissue distribution study in rats showing no brain exposure and a model demonstrating antifibrotic effects of inhaled ensifentrine [3][5] - The effects of ensifentrine on lung fibrosis were evaluated in a rat bleomycin model [5] Group 3: Company Overview - Verona Pharma focuses on developing therapies for chronic respiratory diseases with significant unmet medical needs, with Ohtuvayre being its first commercial product [7] - The company is also developing a fixed-dose combination of ensifentrine and glycopyrrolate for COPD maintenance treatment [6]